Dapagliflozin for hard-to-treat ascites in cirrhosis
Treatments studied
Part of Digestive system, Kidney & urinary clinical trials.
This trial tests whether dapagliflozin, a diabetes medicine that helps remove extra fluid through urine, can reduce fluid buildup in the belly (ascites) that doesn't improve with standard treatments. It is for people with advanced liver disease whose ascites keeps coming back quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with advanced liver disease (cirrhosis) and moderate belly fluid (ascites grade 2).
- Your ascites is 'refractory' – meaning it did not improve after a low-salt diet and high-dose water pills for at least a week, or it returns within 4 weeks after being drained.
- You are not currently taking a medicine like dapagliflozin (called an SGLT2 inhibitor) and have not had a bad reaction to it before.
- You do not have frequent urinary tract infections (2 or more in 6 months, or 3 in a year).
- You do not have severely low blood pressure (below 90/60) or a history of needing medicine for low blood pressure.
- You do not have severe kidney disease (eGFR less than 20, meaning your kidneys filter very poorly).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests if canagliflozin, a diabetes medicine, helps remove extra fluid and reduce scarring in people on peritoneal dialysis (home-based dialysis). It may improve your dialysis results and protect your belly lining.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial studies whether empagliflozin, a blood-sugar–related medicine, can safely improve chronic low blood sodium when you are not too “dry” or have an imbalanced fluid state. It may help stabilize sodium levels and related health symptoms, but you must meet specific blood and organ-function criteria.
Hear when a new Refractory Ascites trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.